BACKGROUND: Atopic dermatitis (AD) has been associated with atopic manifestations (AMs), such as food allergies, asthma, allergic rhinitis, and allergic conjunctivitis.
A topic dermatitis (AD) is a common, pruritic, recurring inflammatory skin disease affecting 15% to 30% of children worldwide. [1] [2] [3] [4] [5] [6] [7] Although it is often viewed as a minor dermatological disorder, studies have shown that AD is a disease with substantial associated costs and morbidity. [8] [9] In the United States, the cost of illness for AD borne by thirdparty payers ranged from $0.9 billion to $3.8 billion annually for privately insured and Medicaid patients under 65 years of age. 10 This disorder has increased in prevalence 2-to 3-fold since 1970. 3 
Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis-Analysis of Administrative Claims
• Patients with atopic dermatitis (AD) are more likely than those without AD to present with atopic manifestations (AMs) such as asthma (odds ratio [OR] = 1.45-2.17), allergic conjunctivitis (OR = 2.10), allergic rhinitis (OR = 1.53-2.51), and food allergies (OR = 3.20-6.14); however, these figures represent concomitant associations, not assessments of AM emergence in patients who first developed AD.
• Compared with patients without a diagnosis code for AD on a medical claim, the relative risk (RR) of developing AM in patients with at least 1 medical claim with a diagnosis of AD was 1.20 for asthma, 1.35 for allergic rhinitis, 1.50 for allergic conjunctivitis, and 2.35 for food allergy, with an overall RR of 1.33 (95% CI, 1.28-1.38).
• A subsequent diagnosis of AM in AD patients was associated with total medical costs that more than doubled in the subsequent 12 months ($820 per patient) compared with the 12 months preceding the AM diagnosis ($338 per patient), representing a $3.81 per member per year incremental cost due to AD across the entire enrollee population.
What is already known about this subject

What this study adds
Note: An editorial on the subject of this article appears on pages 810-11 of this issue.
AD has been knownt op recedet he development of asthma andallergicrhinitis andissometimes describedasthe firstmanifestation of an ato picdiathesis. [11] [12] Previous researchersreported that patients with AD more commonly presented with atopic manifestations such as asthma (oddsratio [OR] =1.45-2.17), allergicc onjunctivitis( OR =2.10),a llergic rhinitis (OR=1.53-2.51), andf ood allergies (OR=3. 20-6.14) ,c ompared with patients without AD;h owever, thesef igures representc oncomitant associations,n ot assessmentso fa topic manifestation( AM) emergence in patients whofirst developed AD. 10, 13 TheprevalenceofAMs in patients with AD has been reported to be age-dependent, with approximately 43%to53% of children whos ufferedA Ds ubsequentlyd evelopinga sthmaa nd 45%t o 78%d eveloping allergicr hinitis. [14] [15] Severity of AD is positively correlated with eventualA Md evelopment. 15 AMsr educet he qualityoflifefor theaffected individualsand impose an economic burden on thefamily, community, andthe national health care budget. [8] [9] However, ther eduction of AD severity throught reatment intervention with ketotifeno rc etirizinei nc ertain patient groups maydelay theprogressionofAM. 12, [16] [17] [18] Althoughi ti sap revailing concept, thec ausal relationship betweenADand AM currentlyremains uncertain. Recent reviews question then atureo ft he associationb etween allergic sensitization andchildhood eczema,indicatingthatthe high prevalence of childhood eczema in industrializedc ountries mayb ed ue to spurious factorss ucha sm icrobial stimulationa nd affluent westernl ifestyles, rather thant he direct resultso fa topy. 19 The MulticenterAllergy Study, aprospectiveinvestigation of thenaturalc ourse of AD in children from birtht oa ge 7, foundt hatt he presence of earlyADw as notassociated with school-age asthma except in children with earlyw heezing . 20 Thus more cohort studiesthatexamine theroleofADinthe incidenceofsubsequent AM areneeded. Moreover,the treatmentcostsattributabletoAMs in patients with AD have notyet been evaluated.
Theobjectives of this studywereto( 1) assess therelativerisk of developing AMs( asthma,a llergic rhinitis,a llergicc onjunctivitis, andf ood allergies)i np atientsw ho were newlyd iagnosed with AD compared with patients without AD,( 2) estimate the incremental costsa ttributablet oA Mt reatment in patients with AD by comparingtotal treatmentcostsbeforeand afterthe onset of AM,and (3)identifythe factorsassociatedwiththe incremental costs.
■■ Methods
Data Source
This studyu sedM arketScan databasest hatc ontained medical (inpatient anda mbulatory) ando utpatientp harmacyc laims with dateso fs ervice from January1 ,1 999,t oD ecember 31, 2004 .These data arecollected from approximately100 insurance companies int he UnitedS tatesc overingm oret han3m illion employeesa nd dependentse nrolledi nt he health benefit programsoflarge employers, people whoacceptedhealth insurance throught he Consolidated OmnibusB udgetR econciliationA ct (COBRA), earlyretirees, andMedicare-eligible retirees.
StudyCohortfor Patients With AD (ADCases)
In this retrospectives tudy,w ei dentifiede ligiblec ohort patients with AD within a12-monthindexperiodfromJanuary 1, 2000, to December 31,2 000.P atientsw erec onsideredt oh ave AD if they hada tl east 1m edical claim with ap rimary or secondary diagnosisf or AD ( International Classification of Diseases,N inth Revision,C linicalM odification [ICD-9-CM] codeso f6 91.8x) or contactd ermatitiso ro ther eczema of unspecifiedc ause (ICD-9-CMcodes of 692.9x)duringthe indexperiod. 10 Thedate of thefirst AD diagnosisduringthe indexperiodwas defined as theindexdate.
To select newlyd iagnosed AD patients whod id noth ave AM diagnosis, we excluded patient si ft heyh ad ad iagnosis of AD or AM at anytimed uringthe 12 months prior to theindex date.Ad iagnosis of AM wasd eterminedo nt he basiso fa ny of thef ollowing diagnosisc odes:a sthma( ICD-9-CM codeso f 493.xx), allergic rhinitis (477.xx),a llergic conjunctivitis (372.05 or 372.14), or food allergy( 693.1x,6 92. 5x,9 95.60). 10, 13 Patients diagnosedw ithb othA Da nd AM on thei ndex date were excluded.
Alli dentifiedA Dp atientsh ad continuous health and prescription coverage from 12 months prior to thei ndex date througha tl east 24 months a fter thei ndexd atea nd were followed untilt he endo ft he studyp eriodo rl osso fc overage. AD patients whod eveloped AMsd uringt he follow-upp eriod were included in thea nalysiso fA M-relatedc ostso nlyi ft hey had( 1) at least1 2m onthso fe ligibility from thei ndexd ate (ADd iagnosis)t hrought he AM diagnosis date,a nd (2)a tl east 12 months of eligibility from theA Md iagnosis date untilt he endofthe studyperiodorlossofcoverage.
Cohortfor Patients WithoutAD(AD Comparisons)
To comparet he incidenceo fA Ms betweenA Dp atients and non-AD patients,ac omparison cohort wass elected.P atients were eligible fori nclusion in thec omparison cohort if they had at least1outpatientvisit forany reason during theindexperiod (January1 ,2 000,t oD ecember 31,2 000)a nd didn ot have anyc laimsf or diseases relatedt os kina nd subcutaneous tissue (ICD-9-CMc odes 690-698, 373) basedo na ll 5d iagnosis fields on thec laim at anyt imed uringt he entire studyp eriod. The indexdatef or thecomparison cohort patients wasassigned to thed ateo far andomlys elected outpatientv isit during thei ndexp eriod. Ar andomlya ssignedd atew as useda st he indexdatebecause thesepatientsdid nothave an AD diagnosis date.T hese potentialcomparison cohort patients were excluded if they hada ny claimsw itha nI CD-9-CMc odef or AM during the1 2-monthp re-indexp eriod. Allc omparison cohort patients hadcontinuous health andprescriptioncoveragefrom12months before theindexdatetoatleast 12 months afterthe date.
Data Analysis
Case-ComparisonMatchingProcedure
In an effort to controlf or thee ffectso fc onfounding stemming from baseline differences in prognostic characteristics,c ases andc omparisonsw erem atched usingap ropensitys core. [21] [22] Propensity scores were derivedfromalogisticregression, which predictedt he likelihood of beinga nA Dc aseu sing 90 predictivec ovariates, includingd emographic characteristics (age, gender,g eographicr egion, health insurancet ype),C harlson ComorbidityI ndex, pre-period number of hospitalizations and physician office visits,t ypeo fh ealth insurancec overage, preperiod use of medications (antibiotics,cardiac drugs, estrogens/ contraceptives,n onsteroidal anti-inflammatoryd rugs (NSAIDs), andc yclooxygenase-2 (COX-2)i nhibitors, ando ther comorbidities representingawidevarietyofbodilysystems(acomplete list is availablef romt he authorso nr equest).T he propensity score wasu sedt om atchc ases with comparisonsu sing ag reedy matchingm ethod, whichp airs each case patientwithau nique comparison patientbased on thecloses tpropensityscoreswithout replacement. 23 Themeanofc-statisticswas 0.71 (range from 0.68 to 0.74), whichw as sufficient to ensure thea bility of propensitys corest oe ffectivelyd ifferentiate betweenA Dc ases and comparison patients. 24 To enhancet he precisiono ft he matching process,w e stratified patients in each groupb ya ge group( i.e.,<20,2 0-40, 41-64, and> 64 years),a nd indexd ateb ased on a6 -month interval (i.e., 2g roups).W ithin each stratified block,e ligible AD patients were initiated to matcho na1 :1 ratiow ithe ligible comparison patients on theb asis o fi dentical 6 -digit propensity scores.I ft he matchingw as unsuccessfulw ith6 -digit scores, it wasa ttempted with identical5 -digit scores.T hism atching process wascontinueduntil patients were matchedwithidentical 2-digitscores. AD patients notmatchedwithcomparison patients at 2-digitscoreswereconsidered unmatchedand were excluded. If an AD patienthad more than1matchablecomparison patient, 1ofthe comparison patients wasrandomlyselected.
DevelopmentofAMs
To measurethe incidencerateo fAMs,w em easuredtimet othe developmentofthe firstAMtype(asthma,allergic rhinitis, allergic conjunctivitis,o rf ood allergy)after theindexADdiagnosis.T he rationalebehindthis approachwas that thefirst type of AM would change theriskofother typesofAMeventsand risk factors.
Theincidence of AMsper 100,000 person-years wascalculated to adjust forthe different observationperiodf or each patient. [25] [26] Time-to-eventcurvesd escribingthe proportion of patients who developed AMswereplotted usingthe Kaplan-Meier method,and thetrendswerecompared usinglog-rank tests. Because patients couldd evelop any1o ft he 4t ypes of AMs, theL unn-McNeil method of competingrisksurvivalanalysiswas usedtocalculate both crude( unadjusted)and adjusted relative risks; adjustments were based on gender,region, hospitalization, outpatientvisit,use of drugs(antibiotics,antihistamines, cardiacdrugs,and NSAIDs/ COX-2s), andcomorbidities(diabetes,hypertension, andischemic heartdisease). 27 This approachallowed only 1Cox proportional hazard modeltoestimateseparate relative risksoffactors associated with developing each type of AM.P lots of log-logs urvival curves were usedtotestthe assumption of proportional hazard.
IncrementalCosts AttributabletoAMs
Treatmentc ostsa ssociated directly with medicals ervicesa nd prescription drugsf or AD andAMs were calculated bysubtractingt he member cost-share amount from thea ctualp ayments made by thethird-party payer. Medicalservicesassociatedwith AD or AMsw eret hose services usedw henA Dp atientsv isited theirphysician offices( or outpatientdepartment) or were hospitalized. Theseserviceswereidentifiedbased on ICD-9-CM codes (asd escribed in thes ectiona bove fors tudy cohort)i nt he first 2diagnosis fields of theclaim.Prescriptiondrugs usedfor AD or AMswerebased on therecommended medications fortreatment of thesed iseases( Table1 ). Thesed rugs were identified based on theN ationalD rugC odea nd American Hospital Formulary Servicetherapeutic classes.
AD patients whod eveloped AMsa tl east 1y eara fter AD diagnosisw erei ncludedi nt he calculationo fi ncrementalc osts associated with AM.T oensurethatcost calculations were based on time periodso fe qual length,t he annual incrementalc ost attributable to AM wasc alculateda st he differenceb etween (1) AD-onlycostsinthe 12-month period before thedevelopment of AM and(2) AD+AMcostsinthe 12-month period afterdevelopment of AM.T hisa pproachw as tak en to minimize bias in cost estimationdue to variancesinpatient characteristics anddisease severities.
Some medications( e.g.,s ystemicc orticosteroids,a ntihistamines),a ss hown in Table1 ,c an be usedt ot reat both AD and varioust ypes of AMs. If an AD patientu sedt he medication before thedevelopment of AM,the medicationcost wasattributed to AD treatment. If an AD patientu sedt he samem edication both before anda fter thed evelopment of AM,u se of them edicationb eforeA Mw as included in AD treatment costs, andu se of them edicationa fter AM wasi ncludeda sp arto ft he total AD+AMt reatment cost.A9 5% confidencei nterval( CI)f or them eani ncremental costsw as calculated usingt he bootstrap method andt he differences in costsb eforea nd afterA Mw ere tested usingpaired t test. 28 Factorsi nfluencing thea mounts of thei ncrementalc osts attributable to AM treatmentw ered eterminedu sing ag eneralized linear modelw ithl og-link function,c ontrolling fort ypes of AMs, patientd emographic characteristics (e.g., age, gender), andseveral factorsmeasuredduringthe 1yearprior to theindex date:(1) treatment intensitydefined as number of physician office visits andh ospitalizations, (2)c omorbid conditions,and (3)use of antibiotics,c ardiac drugs, estrogens/contraceptives,N SAIDs/ COX-2inhibitors, or gastrointestinal medications.
Allc ostsw erec onverted to year 2005 dollars usingt he consumer pricei ndexesf or inpatienth ospitals ervices, medical services,and prescription drugs, accordingly. Allstatistical tests were 2-sidedatthe 5% levelofsignificance andwereperformed usingSAS software,version 9.1 (Cary, NC). 30 
■■ Results
As depicted in Figure 1 , this studyi dentifiedatotalo f4 7, 259 AD patients from MarketScan databases. Amongt hese AD patients,3 1,969( 67.7%) weres uccessfullym atched1 :1 with randomly selected non-AD patients usingt he propensity score method.B eforem atching, patients in thes tudy groupw ere significantlyd ifferent from thosei nt he comparison groupf or most variables; butafter matching,the AD andn on-ADc ohorts didn ot significantlyd iffer with respect to anyo ft he patient characteristics factored into theADpropensityscore (Table 2) .
Thei ncidence rateso fA Ms per1 00,000 person-years (PYs) forthe AD andnon-ADpatient groups arecompared in Table3 .
Overall, 21.8%o fA Dp atientsd eveloped at least1t ypeo fA M during thef ollow-up period,w hile 16.9%o fn on-ADp atients developed AMs( adjusted relative risk [RR] =1.33, 95%C I, 1.28-1.38).T he incidencer ates per1 00,000 PYsw eree stimated to be 5,284i nA Dp atientsa nd 4,493i nn on-ADp atients. AmongA Dp atients, 14.6%d eveloped allergic rhinitis, 5.3% were diagnosedwithasthma, butonly1.6%and 0.3% developed allergic conjunctivitis and food allergies, respectively. Among non-AD patients,the incidencerates of the4types of AMswere significantlylower than thoseofADpatientsbut similarpatterns in thei ncidence of each type of AM were observed.T he trends of cumulative probabilities of developing anyA Ms showed that theriskofdevelopingAMs wassignificantlyhigherinADpatients thaninnon-ADpatientsovertime(logrank test, P <0.001).
AmongADpatientswho developedAMs,allergicrhinitiswas them ost frequentm anifestation( 66.3%),f ollowedb ya sthma (24.8%), allergic conjunctivitis (7.6%),a nd food allergy( 1.8%) (datanot shown).
At otal of 5,599A Dp atientsh ad at least1 2m onthso f coverage prior to andfollowing thedevelopment of AM andwere included in theA Mc ost analysis (Table 4) .T he mean annual treatmentc ostsa ttributablet oA Mt reatment were $482 (95% CI,$452-$505)per patient, representingacost nearly 2.5times theA D-only cost,f rom$ 338p rior to developmento fA Ms to $820 afterd evelopment.T he incrementalc ost of $482 perA D patientw ho developedAMc an be extrapolated to be $3.81 per member pery ear( PMPY)a crosst he population of members (i.e.,$ 482p er patient×7 91 more patients [5,284 AD patients whod eveloped AM minus4 ,493 comparison patients who developed AM]=$381,000 extra costsa ttributablet oA Mt reatment per1 00,000 members).A bout 50%o ft he incremental cost wasassociatedwithmedical services receivedatphysicians' officesorhospitals ($243) andthe rest wasassociatedwithuse of prescription drugs( $239).
When AD patients developedAM, theirincremental costs attributable to asthma were estimated to be $973,f ollowed by allergic rhinitisat$341, food allergyat$257, andallergic conjunctivitis at $99 ( Figure 2) .A fter controlling fors tudy variablessuchasage andgender,itwas estimated thatwhen AD patients subsequentlyd eveloped allergic rhinitis, their predictedt reatment costsw ere4 5% of thet reatment costs forA Dp atients whod eveloped asthma (Table 5) .O lder patients usedm orer esources to treatt heir AMs; patients aged ≥ 65 years incurred 28%m orec ostsc ompared with patients <21y ears.P atientsw ho made frequentv isits to theirp hysician's office incurred substantiallyl arger expenditures.
■■ Discussion
This retrospectivep opulation-basedc ohort studye stimated ther elativer isko fd evelopingA Ma nd detailed incrementalc ostsa ttributablet ov arious AM conditions amongA D patients.A Dp atientsw ere3 3% more likelyt od evelopA M than non-AD patients.A fter AD patients developedA M, thet reatment costsi ncreased from $338 to $820,r esulting in $482 of incremental costsa ttributablet oA M( P <0.001) perADp atient. From theperspectiveo fthe third-party payers, thet reatmentc ostsa ttributablet oA Mi nA Dp atients aree xtrapolated across thee ntirem embership to be $3.81 PMPY.T hese resultss upport thef indingso fp reviouss tudiest hatp atients with AD arep redisposedt ot he subsequent developmento fA Ms,w hich,i nt urn, usesm oreh ealth care resources, andthattreatment of AD patients with ketotifenor cetirizine coulddecreasethe risk of developingAMs. [11] [12] [13] [15] [16] [17] [18] In ours tudy of newlyd iagnosed AD patients of all ages,w e estimated thei ncidence rate of AMst ob e2 1.8%, whichw as significantlyh ighert hant hato ft he matchedn on-ADp atients (16.9%). AD patients hadah igherr iskt hann on-ADp atients of developingt he followingm anifestations:f ood allergy by 2.35 times, followed by 1.50 timesf or allergicc onjunctivitis, 1.35 timesf or allergicr hinitis, and1 .20t imes fora sthma. The estimated relative riskso fh avingA Ma mong AD patients in ours tudy were lowert hant hose reported in theE llise ta l. studyt hate stimated theO Rs compared with non-AD patients of 2.17 forasthma, 1.53 forallergic rhinitis,and 2.10 forallergic conjunctivitis. 10 Thed iscrepancy betweent he studiesm ay be duet od ifferencesi nt he characteristics of studyp atients andd efinitionso ft he AM conditions,s ucha sa llergicc onjunctivitis. Ellise ta l. included aM edicaidp opulationt hat, when compared with thep rivatelyi nsured patients,h ad as ignificantlyh igherp revalenceo fa sthma( 14%v s. 5%)a nd allergic conjunctivitis (7%v s. 4%). Ellise ta l. also usedam oreg eneral definitionfor allergic conjunctivitis that included otherdisorders of conjunctiva.
Despitet he high prevalence of AD,w hich wase stimated to affect 15.2 million people in theU nitedS tatesi n2004, 31 the economic burden of thedisease hasreceivedlittleattention,with only afew studiesexaminingthe cost of AD.Because of thedifferences in health care delivery andfinancing systemsaswellas thev ariation in studyp atient diseases everity andc ost componentsincludedinthe study, largevariationscan oftenbefound in theestimationofthe medical treatment costsassociatedwithAD across differentc ountries,ranging from aper capita cost of $71 in theN etherlands ($93 in 2005 dollars) to $2,559 in Germany ($3,300i n2 005d ollars). 8, [32] [33] [34] [35] [36] [37] Forthe samer easons,d irect comparisons of thec ost estimates in theses tudies with ours are generallydifficult. Nevertheless,r esults of theses tudiesd emonstratedthatADimposed considerable psychosocial andfinancial burdensonthe family andthe community. Astudy that assessed costsf romap ayer'sp erspectivee stimated annual treatment costso fA Da nd eczema to be $580 ($816i n2 005d ollars) forp rivate insurers and$ 1,250( $1,758 in 2005 dollars) for Medicaid. 10 Thesee stimates were substantiallyh igherthano urs because they were basedo npossibleAD/eczema-related claims. However,w henf ocusingo nlyo nm edical servicec laimsf or AD/eczema( excludingp rescriptiond rugs), Ellise ta l. 10 found prior estimatedc ostso f$ 85 ($119i n2 005d ollars)f or thep rivately insuredpatientswithADthatw erecomparablewithour AD-only(prior to thedevelopment of AM)estimateo f$88 ($84 foroutpatientvisitsand $4 forhospitalizations).
AfterA Dp atientsd eveloped AM,t heir treatmentc osts increasedb y$ 482( from $338 to $820), estimated as thedifferencesinmedical treatmentcost associated with AD or AMsbefore andafter development of AMs. Of the4types of AMsevaluated, asthma proved to be themost expensivetotreat,withanannual incrementalc ost estimated at $973 perp atient,a pproximately 3t imes thato fa llergic rhinitisa nd food allergy anda bout 10 timesthatofallergic conjunctivitis.
Oure stimationo fc ostsa ttributablet oa sthmat reatment fallswithin therange of $430 ($668in2 005d ollars)t o$ 1,095 ($1,719 in 2005 dollars)r eportedi n2p reviousn ational studies. [38] [39] Thel ower estimate, by Weisse ta l. averagedt he cost fora ll self-reporteda sthmap atientsi dentifiedf rom theNationalHealth InterviewSurvey, whichmay have included asthma patients whod id notr equirem edical attentionf or theirc onditions. 38 In contrast,S mith et al.c alculatedt he per capita cost amongu sers of health care services usingt he 1987 NationalMedical ExpenditureSurvey, yielding thehighercost. 39 Thel arge difference betweent he cost reported by Smithe ta l. andb yu sm ay be duet ov ariationsi nt he definitiono fm edi-cals ervicesa nd prescription drugsu sedf or asthma treatment. In addition,Smith et al.usedamoregeneral inclusioncriterion fora sthma-relateds ervices, whichu sedu pt o4ICD-9-CM codesf or each encounterincontrastt othe use of only 2inthe presentstudy.
Thee stimated annual costso f$ 341p er patientf or treatment of allergicrhinitis is comparablewith$246($355 in 2005 dollars) estimated from thew orkb yL aw et al., 40 and$ 256( $376 in 2005 dollars) by Malone et al. 41 In ours tudy as well as in these previous studies, average treatmentc ostsf romu sers of health care services were estimated.H owever,i th as been foundt hat onet hird of patients with allergicr hino-conjunctivitisd id not use anyh ealth care services or prescription drugs 40 ;o nly 12%s ought medical treatmentf or allergicr hinitis. 41 When treatmentc ostsw erea ssessed basedo nt he self-reports of patients with allergic rhino-conjunctivitis from theN ational Health InterviewS urvey, whichi ncludedp atientsw ho mayn ot have useda ny health services,p er patientt reatment costsw ere estimated to be as lowas$ 70 ($99 in 2005 dollars). 42 Thus,c ost estimatesf romv arious studiess houldb ec arefully interpreted ande xtrapolated when assessingt he national economicb urden of allergicrhinitis.
Fewerp atientsd eveloped af ood allergy, butt he incremental 12-month treatment costsa ssociatedw ithf ood allergiesw ere estimatedat$ 257. Since, to ourknowledge,there aren ostudies of thec ostso ff ood allergyi nt he literature,n od irect comparisons couldb em ade. Food allergies arer eportedt of requently coexistw itha sthmai nc hildren, so it is possible that avoidingf ood allergensm ay improvec ontrol of asthma in selected children. 43 To thebestofour knowledge, this is thefirst population-based studydesignedtoestimatecostsattributabletoAMtreatmentin patients whowerediagnosed with AD.Because theestimates of treatmentc ostsw ereb ased on thei nformation derivedf roma largeh ealth insurancec laimsd atabase, our estimationsr eflect real treatmentc osts( i.e.,t he actual paymentt oh ealth care providersb yh ealth insurancec ompanies)ratherthanestimates basedo np atient-reportedm edical resource utilization and costs, whichm ay be subject to patientr ecall bias ande rrorsi n estimatingprognosis. 
Limitations
Foremost among the study limitations is that establishing a causal relationship between AD and AM is not possible using administrative claims. At best, longitudinal analysis of administrative claims permits identification of a temporal relationship. While our methods identified newly diagnosed AD patients without an AM diagnosis based on the 12-month pre-index period (i.e., no AD or AM during the pre-index period), we cannot be certain that AD preceded AM because of a short 1-year pre-index period. Second, in the matching of AD patients with non-AD patients within stratified blocks, propensity scores were applied to control for various risk factors, but the results may be influenced by other variables not recorded in the data set, such as clinical severity of disease or laboratory test results. Third, there is a potential source of bias due to the possible misclassification of AD or AMs based on patients identified via ICD-9-CM codes on medical claims and from pharmacy claims data. We attempted to adjust for the differences between the AD and comparison cohorts to minimize bias, but the impact of differential or nonrandom misdiagnosis bias cannot be ruled out. Although the use of insurance claim databases offers many advantages over self-reported disease databases, misdiagnosis or under-diagnosis of AD may be unavoidable. 10 If random misclassification occurs between the AD and comparison cohorts, then the bias of the relative risk would be toward the null (i.e., 1.0). However, if the misclassification is not random, then the bias may inflate the relative risk. [45] [46] Fourth, the prescription drug costs were calculated based on the dispensing of the medications approved by the U.S. Food and Drug Administration (FDA) for treatment of AD or AM, but we cannot ascertain whether the prescribed medication was indeed used for the FDA-approved indications.
Fifth, theincremental costsassessed in this studyrepresent direct medicalcostsand thereforeunderestimatethe totalcosts to thesociety becau se thetreatment cos ts were basedsolely on thea mounts actually paid by health insurancec ompanies to health care providers. We didnot includecostsassociatedwith self-treatment usingo ver-the-countero ra lternative remedies, burden on family members,a nd loss of productivity 9, 47 ;t hus, cautioni sa dvised in generalizing thee stimated treatment costsf romt hiss tudy.As ixth limitationi st he calculationo f incrementaltreatment costsbased on ashort follow-upperiod of 1yearafter AM diagnosis. Nonetheless,thislimitationmay have minimale ffect on cost estimation because incremental costswerecalculatedasthe differenceincostsbeforeand after developingAMs in thesamep atient to minimize inter-patient variation.
Because AD createsa ne conomic burden to some patients, families,and society, educationalprogramsfor patients or families of children with moderate to severe AD as well as psychosocial supportfor parentscould decrease theirburdens through loweredt reatment costsa nd improved outcomes. 48 In addition, cost-effectiveness studieso nd ifferent treatmentr egimensc an be recommendedt od ecreaset he economic impact of AD on society.
■■ Conclusion
We foundthatpatientswho hadADweremorelikelytodevelop AMscompared with non-AD patients (RR=1.33),withthe highesti ncreases in risk forf ood allergy (RR=2.35), followed by allergic conjunctivitis (RR=1.50), allergic rhinitis (RR=1.35), andasthma(RR=1.20).The totaltreatment costsinADpatients whod eveloped AMsa tl east 1y eara fter AD diagnosisw ere about 2.5times thecostsrequired to treatADalone. 
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